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Background: Health-related quality of life (HRQoL) is most adversely affected in cancer patients between diagnosis
and the end of chemotherapy. The aim of the Complementary Nursing in Gynecologic Oncology (CONGO) study is
to assess the effectiveness of a complex nursing care intervention of CAM to increase HRQoL in cancer patients
undergoing chemotherapy.
Methods/design: CONGO is a prospective partially randomized patient preference (PRPP) trial including adult
women diagnosed with breast and gynecologic cancer starting a new chemotherapy regimen. Patients without
strong preferences for CAM will be randomized to usual nursing care or complex nursing care; those patients with
strong preferences will be allowed their choice. The intervention consists of three interacting and intertwined elements:
CAM nursing intervention packet, counseling on CAM using a resource-oriented approach and evidence-based
informational material on CAM.
Primary outcome data on participants’ HRQoL will be collected from baseline until the end of treatment and long-term
follow-up using the EORTC-QLQ-C30. Secondary outcomes include nausea, fatigue, pain, anxiety/depression,
social support, self-efficacy, patient competence, spiritual wellbeing, and satisfaction with care. Accompanying
research on economic outcomes as well as a mixed-methods process evaluation will be conducted.
A total of 590 patients (236 patients in the randomized part of the study and 354 patients in the observational part of
the study) will be recruited in the two outpatient clinics. The first analysis step will be the intention-to-treat (ITT) analysis
of the randomized part of the trial. A linear mixed model will be used to compare the continuous primary endpoint
between the intervention and control arm of the randomized group. The observational part of the trial will be analyzed
descriptively. External validity will be assessed by comparing randomized with nonrandomized patients.
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Discussion: Cancer patients are increasingly using CAM as supportive cancer care, however, a patient-centered
model of care that includes CAM for the patient during chemotherapy still needs to be evaluated. This protocol has
been designed to test if the effects of the intervention go beyond potential benefits in quality-of-life outcomes.
Trial registration: German Clinical Trials Register (DRKS), DRKS00006056 (15 April 2014).
Keywords: Breast and gynecologic malignancies, Integrative oncology, Complementary and alternative medicine
(CAM), Counseling and nursing, Complex interventions, Health services research, Quality of lifeBackground
Gynecologic malignancies, including breast cancer, con-
stitute approximately 95,600 new cases per year, which is
nearly half (43%) of all malignancies in women in
Germany [1]. It is known that health-related quality of
life (HRQoL) is most negatively affected from the time
of diagnosis through the completion of chemotherapy
[2]. In this demanding phase, many patients are looking
for help and orient themselves towards the field of com-
plementary and alternative medicine (CAM). Conse-
quently, the use of CAM by cancer patients has
increased considerably over recent years [3], particularly
in breast cancer populations [4].
Research suggests that cancer patients use CAM
alongside their conventional therapy for a variety of rea-
sons [5,6]. For example, patients use CAM to improve
their HRQoL (for example, to relieve stress and anxiety
and to alleviate side-effects of the chemotherapy) or they
are motivated by the desire to maximize the success of
treatment through their own actions (‘self-efficacy’) [3,7].
Overall, CAM use constitutes a form of coping strategy
that helps cancer patients and their involved significant
others (SOs), like family members and close friends, to
overcome the distressing cancer diagnosis [8].
In a German sample of 1,030 patients with gynecologic
and breast cancer, CAM was used by 49% of all women
(50% in breast cancer patients versus 44% in gynecologic
cancer patients). In this study, CAM users less fre-
quently stated an overall deterioration of their health
status (35%) compared to nonusers (50%) [9]. These
numbers are in line with international studies where the
rate of CAM use in women with breast cancer has been
reported to be even higher (up to 75%), with the highest
percentages in women undergoing chemotherapy [10].
Worldwide, oncologists have acknowledged that CAM
may contribute positively to patients’ psychological and
physical well-being and have started to develop guide-
lines on integrating CAM within a quality-controlled,
evidence-based strategy [11-13] concluding that there is
a lack of expert guidance available to patients. It has
been suggested that oncology nurses are in a key pos-
ition to evaluate which symptoms or side-effects patients
are experiencing and to identify which CAM therapies
may be helpful for symptom control related to treatmentand psychological distress due to their cancer and the
chemotherapy [14,15].
Internationally, oncology nurses have responded to
this high patient demand for CAM by incorporating se-
lected CAM therapies such as acupressure or the appli-
cation of essential oils by massage, packs or compresses
within their everyday practice. In several countries (for
example, the United States, Canada, and the United
Kingdom.), nursing schools have resumed the incorpor-
ation of CAM into their educational curricula and nurs-
ing standards [16]. Furthermore, nurse-led CAM
education programs for patients or services for individu-
alized patient consultations have been established [17].
In Germany, CAM therapies have been increasingly
integrated into nursing practice, particularly in oncology
and palliative care settings [18-20]. These kinds of inter-
ventions, often accompanied by individual patient coun-
seling, require additional time inputs to daily routine
care. Therefore, staffing shortages and time restrictions
can impede the integration of CAM into nursing care.
Attempts to do so, with the existing conditions in our
health care system, have not been frequent, and the ef-
fectiveness of CAM nursing interventions in routine
clinical practice still remains to be evaluated. Consider-
ing both the demand of cancer patients for CAM and
also the possible risks in certain cases due to poor infor-
mation and/or communication [21], CAM interventions
should be systematically researched and, based on evi-
dence, structures accordingly adapted.
Levine’s conservation model [22] provides a valuable
theoretical framework for guiding and promoting a com-
plex CAM intervention aimed at increasing health-
related quality of life in cancer patients undergoing
chemotherapy. According to this model, the individual is
posited as a spiritual, holistic being experiencing mean-
ing in social relations [22]. For maintaining or re-gaining
health, and experiencing a state of wholeness, the indi-
vidual tends to adapt by the conservation of energy,
structural integrity, personal integrity, and social integ-
rity. Based on Levine’s conceptual model, it has been
suggested that nurses can support cancer patients in the
process of adaptation after a distressing cancer diagnosis
and treatment by addressing the patients’ conservation
strategies, so that patients can find back to a state of
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servation principles guided the development of the
current study’s intervention, and the identification of
patient-centered outcomes.
Thus, the Complementary Nursing in Gynecologic
Oncology (CONGO) study was initiated as a prospective
partially randomized controlled intervention study to in-
vestigate the effects of a complex nursing care interven-
tion on HRQoL and a wide range of clustered symptoms
in female cancer patients undergoing chemotherapy. As
patients are rarely neutral towards CAM, this study con-
siders patients’ preferences for receiving or not receiving
the intervention. By assessing the quality of life out-
comes and evaluating the processes of the intervention,
it is anticipated that the CONGO study will provide
evidence-based information on integrated health care
services relevant for the treatment of cancer.Methods/design
The study protocol received the approval by the ethics
committee of the University of Heidelberg (S-008/2014) as
well as the ethics committee of the State Medical Council
of Baden-Wuerttemberg (B-F-2014-037), and is registered
with German Clinical Trials Register (https://drks-neu.
uniklinik-freiburg.de/drks_web/) under DRKS00006056.Objectives
The primary outcome of the CONGO study is cancer
patients’ HRQoL. It will be assessed if cancer patients,
starting a new chemotherapy regime, benefit from a
complex nursing care intervention, consisting of a CAM
intervention packet (for example, aromatherapy, mas-
sage, compress, acupressure), counseling on self-help
CAMs, and evidence-based informational material on
CAM, regarding HRQoL in comparison to patients re-
ceiving usual nursing care.
Secondary outcomes are to assess the effects of the
complex intervention on a wide range of physical and
psychosocial symptoms including nausea, fatigue, pain,
anxiety/depression, social support, self-efficacy, patient
competence, spiritual wellbeing, patient satisfaction, and
the quality of life of patients’ significant others (SOs).
Furthermore, accompanying research on health eco-
nomic outcomes will be conducted.
In addition, the acceptability and feasibility of the
complex intervention will be evaluated in the two
recruiting centers by providing a thorough process
evaluation and information about the provision of inte-
grated cancer care in outpatient cancer services. There-
fore, quantitative data will be collected that will be
supplemented with qualitative interview data involving
healthcare staff, patients, and their SOs.Design of the study
The CONGO study has been designed as a partially ran-
domized patient preference (PRPP) trial for the following
reasons: randomized clinical trials (RCT) are the gold
standard for establishing the efficacy of medical treat-
ments [25,26]. Randomization has the key advantage of
controlling for both known and unknown confounders
and the elimination of their influence on the treatment
outcome. However, patients often have a preference for
a treatment. In such case, randomization might fail
(preference effect) [27]. Patients with strong preferences
are more likely to decline participation in a RCT because
randomization does not guarantee that they will get
what they want. If a large number of patients refuse
randomization, study results may not be representative
of the whole population, and the external validity of the
trial will be negatively affected. On the other hand, if pa-
tients with strong preferences consent to randomization,
this may affect the internal validity of the trial because
randomization cannot deal with the post-randomization
effects of patients’ preferences on outcomes [28].
If the current study would follow a purely standard
RCT design, patients with strong preference for CAM
will be pleased when assigned to the ‘complex nursing
care intervention on CAM’ group and disappointed
when assigned to the ‘usual nursing care’ group. The
preferences will, thus, affect the HRQoL assessment
within the trial. Therefore, the current study has been
designed as a partially randomized patient preference
(PRPP) trial. Patients with strong preferences will be
allowed their choice, and those without (strong) prefer-
ences will be randomized to usual nursing care or com-
plex nursing care (see Figure 1).
The PRPP design allows for recruiting a higher num-
ber of patients, which increases the external validity and
generalizability of the results [29]. Measurement bias
due to patients being disappointed by their treatment al-
location will be minimized, as these patients will not be
randomized and allowed their desired treatment without
randomization. In addition, the PRPP design enables
comparisons between patients with and without a pref-
erence and an exploration of patients’ characteristics as-
sociated with preference.
A disadvantage of the PRPP design is that the prefer-
ence (= observational) arms suffer from selection bias
and are therefore susceptible to unmeasured con-
founding. Primary analysis is therefore usually being
performed on the two randomized treatment arms,
which should be large enough to reliably answer the
study question.
Participants and setting
To represent everyday conditions, and for obtaining a
high external validity and generalizability, female cancer
(Baseline TO)
EOT (4 weeks after end of CHT)
Observational 
part of the study
Patient with strong  preference
Randomized 
part of the study 










 nursing care 
intervention on 
CAM
Start of CHT until T2
Midline (after the first half of CHT)
FU (6 months after end of CHT)
Abbreviations: CHT = chemotherapy, EOT = end of treatment, FU = follow-up
Figure 1 Study flow chart. CHT, chemotherapy; EOT, end of
treatment; FU, follow-up.
Klafke et al. Trials  (2015) 16:51 Page 4 of 12patients will be recruited under broad inclusion criteria
(for example, all adult women diagnosed with breast or
gynecologic malignancies starting a new chemotherapy
regimen) from different levels of care (university hospital
and community hospital). All patients registering for a
new adjuvant or neoadjuvant chemotherapy regimen will
be informed about and invited for study participation, ir-
respective of their participation in other studies. The
only exclusion criteria are insufficient knowledge of the
German language, cognitive impairment, and inability to
give informed consent.
Recruitment and randomization
Informed consent will be obtained from all women
before study entry. Breast and gynecological cancer pa-
tients registering for a new chemotherapy regime at the
National Centre for Tumour Diseases (NCT) Heidelberg
and the Community Hospital Karlsruhe will be informed
by flyer, their treating oncologist, or nursing staff about
the CONGO study. Then, a CAM-trained nurse will ap-
proach the potential participant, briefly inform her about
the study and ask her if she would like to have furtherinformation. Those agreeing will be provided with details
of the study verbally and in written form via the study
information leaflet. Patients who agree to participate will
be asked to sign the consent form. After informed con-
sent, baseline assessments will be conducted. The nurse
will assert if the potential participant has a strong prefer-
ence to receive the CAM nursing intervention and allo-
cate her into the observational part of the study if
applicable. All other participants will be allocated into
the randomized part.
The CAM-trained nurses will randomize the study
participants using randomizer.at, which is an online cen-
tral randomization service. Participants will be stratified
by cancer center (NCT Heidelberg/Community Hospital
Karlsruhe) and stage of cancer (curative treatment/pal-
liative treatment), and then randomly allocated at a ratio
of 1:1 to the intervention or control arm of the random-
ized part of the trial. Blocked randomization with vary-
ing block sizes will assure that the numbers in the arms
are balanced, while the nurses are not being given the
possibility to deduce the next allocation. Further, alloca-
tion concealment will be ensured, as the randomization
service does not release the code for the randomization
done by the CAM-trained nurse administering the inter-
vention. Thus, it will be assured that the recruiter has
no knowledge about the random sequence and hence
cannot influence participants due to possible bias.
Intervention group
The complex intervention [30,31] consists of three inter-
acting and intertwined elements tailored to the patients’
needs: CAM nursing intervention packet, counseling on
CAM using a resource-oriented approach and evidence-
based informational material on CAM.
This complex intervention combines existing evidence
and practical experience and was developed by an expert
team consisting of a qualified nursing instructor, nursing
staff experienced with CAM in cancer patients, study
nurses, medical doctors, and researchers specialized in
psycho-oncology, complementary therapies, and health
services research. The CAM nursing intervention packet
was composed during a two-day workshop in February
2014. It was then finalized after several meetings and it-
erative discussions, modifying and concisely summariz-
ing the intervention packet to meet the study’s aim. The
final intervention packet targets a range of physical and
psychological symptoms affecting cancer patients’
HRQoL during chemotherapy administered in an out-
patient setting. The CAM-trained nurse will select an
intervention from the nursing intervention packet and
tailor it to the patient’s individual needs. In addition, pa-
tients receive standardized CAM information sheets
with instructions on how to conduct selected CAM
practices at home. The selection of these CAM
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and psychological concerns, as well as on preferences,
and the nurse’s recommendation. The information
sheets will be included in a diary patients have to keep
during the study.
When patients visit the cancer center for their first
cycle of chemotherapy, they will receive an initial coun-
seling interview. In this interview the nurse will explain
the potential side-effects of the chemotherapy and how
to prevent or alleviate them with usual nursing care or
the complex nursing care intervention on CAM. During
this interview, the nurse will also provide resource-
oriented counseling, in particular informing the patient
about how she can activate her own inner resources (for
example, following a balanced diet and exercise plan,
keeping a positive mind-set by meeting regularly with
their family and friends, getting on with or taking up a
new hobby). This counseling is based on concepts of pa-
tient competence and empowerment [32-34], consider-
ing patients’ request to actively do more to complement
their conventional treatment. CAM-trained oncology
nursing staff will also be responsible for individual pa-
tient counseling on CAM, guiding the patient on how to
cope with physical and psychological symptoms at home.
These nurses will be a liaison person on CAM therapies
whom the patient can contact anytime while on the
chemotherapy regime. Furthermore, study participants
will receive an evidence-based information booklet and a
DVD including further answers and guidance about pos-
sibilities for complementing their conventional cancer
treatment with CAMs. In providing patients further
evidence-based CAM material, patients’ self-management
of their disease will be promoted in a safe way. The devel-
opment process of the complex intervention and the
intervention packet will be described in detail in a
separate publication.
Control group
Control group participants of both the randomized and
observational part of the study will receive usual care
according to the clinic’s standard. All patients receive
medical treatment and supportive care including the ad-
ministration of analgesics or antiemetics. Other supportive
care procedures including counseling or inserting (CAM)
products or techniques that are not yet standardized in
the two recruiting centers but that will be documented
during the whole study phase. Control group patients will
participate in all data collection assessments (question-
naires and patient diary) but will not receive any
CONGO-related interventions mentioned above.
Training of nursing staff
The intervention in the current study will be conducted by
nursing staff, who attended two training modulescomposed for the study in order to achieve standardization
between the two centers. The first module consisted of
training on CAM therapies for oncology nursing and
was taught by a qualified CAM nursing instructor
(www.gisela-blaser.de). All CAM therapies, which will
be applied in the current study, were performed in the
session. Additionally, a CAM nursing manual including
supplementary information for the application of these
CAM therapies was provided. In the second module, the
nurses received training on specific communication/coun-
seling within the intervention. In a simulation exercise
with lay persons (students of the University Heidelberg),
the nurses were trained to conduct study briefings and
resource-oriented counseling interviews (see Intervention
group for further information), and they received manuals
for the study briefing and patient counseling.
Outcome measures
Schedule
All outcome measures are summarized in Table 1. There
are five specific assessment time points, which are illus-
trated in the timeline (see Figure 2):
 T0: Baseline assessment 1 to 2 weeks before the
start of chemotherapy).
 T1: Start of intervention (SOI).
 T2: Mid-line (after the first half of the chemotherapy
regimen; maximum of 12 weeks).
 T3: End of intervention (EOI) (after the end of the
chemotherapy; maximum 24 weeks).
 T4: Follow-up, 6 months after the completion of
chemotherapy (after maximum of 48 weeks).
Instruments
All study participants, from both the randomized and
observational part of the study will be asked to answer
the following instruments in paper-based form (ques-
tionnaire pack and patient diary).
Quality of life (patients)
The main outcome measure HRQoL will be measured
with the global quality of life scale of the European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC-QLQ-C30)
[35-37]. The QLQ-C30 is a 30-item questionnaire devel-
oped to assess the HRQoL and five multi-item func-
tional scales (physical, role, emotional, cognitive, and
social function), three multi-item symptom scales
(fatigue, pain, and nausea/vomiting), and six single items
assessing further physical symptoms (appetite loss, con-
stipation, diarrhea, dyspnea, and insomnia) and financial
difficulties. The global quality of life will be calculated
from two items (item 29 ‘overall health last week’ and
item 30 ‘overall HRQoL last week’) , which are measured
Table 1 Assessments and instruments used in the Complementary Nursing in Gynecologic Oncology (CONGO) study







Health-related quality of life EORTC-QLQ-C30 X X X X X
Secondary outcomes
Nausea MAT X
Fatigue FACIT-F X X X X
Pain (general) VAS X X X X
Anxiety, depression PHQ-9 X X X X
Social support F-SozU K-14 X X X
Self-efficacy SES6G X X X X
Patient competence FEPK 2-57 X X X




Accompanying research (health economy) Mannheimer
Modul RV
X X X
Quality of life SOs WHOQOL-BREF X X X
CQOLC X X X
Others Socio-demographic factors X
Cancer characteristics X
Medical history X
Treatment data X X X X X
EOI end of intervention, FU follow-up, PD patient diary, SOI start of intervention, SO significant other.
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transformed into a scale between 0 and 100 points. In the
planned trial, the HRQoL will be assessed at all assessment
points T1, T2, T3, T4, and weekly in the patient diary.
Nausea
Nausea will be assessed with the Multinational Associ-
ation of Supportive Care in Cancer Antiemesis Tool
(MAT), which is an eight-item scale assessing both acuteT0
  Randomization
T1 T2
  Baseline / SOI    Midlin
after maxweek 1
1-2 weeks   




IC   =   informed consent, ICI  =  Initial counselling interview, SOI = start of interv
Cycle 1 Cycle 2 Cycle 3 Cycle 4
IC ICI
Figure 2 Timeline. EOI, end of intervention; FU, follow- up; IC, informed cand delayed nausea [38]. The MAT is designed to be
used once per cycle on two days, and convinces for em-
ployment in the current study with regard to practicabil-
ity and user-friendliness. The MAT will be included in
the patient diary.
Fatigue
The Functional Assessment of Cancer Therapy - Fatigue
(FACT-F) subscale contains 13 fatigue-specific items,T3 T4
e    EOI    FU
. week 12 after max. week 24 after max.week 
48       
(6 months after 
EOT)
 vary)
ention, EOI = end of intervention, FU  = follow-up
Cycle 5 Cycle 6
onsent; ICI, initial counseling interview; SOI, start of intervention.
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internal consistency and construct validity have been re-
ported [39-41]. The German version of the FACIT did
undergo a specific linguistic validation process (FACIT
translation methodology), and is thus considered as ap-
propriate for use in the current study [42].
Pain
The global rating of pain is assessed by a single-item
pain visual analog scale, which measures patient’s sever-
ity of pain over the previous week [43].
Anxiety, depression
Anxious and depressive symptoms are measured with
the nine-item Patient-Health-Questionnaire (PHQ-9),
which is a validated tool for measuring DSM-IV depres-
sive disorders [44]. The PHQ-9 is a shorter and more
user-friendly form than other depression measurements
and thus is being employed in the current study.
Social support
The original questionnaire about social support
(Fragebogen zur Sozialen Unterstützung, F-SozU) is
a 54-item questionnaire from Germany covering a range
of items about patients’ perception of emotional support,
practical support, social integration, burden from the so-
cial network, reciprocity, availability of a confident, and
satisfaction with social support; and has provided high
reliability and validity [45]. We will employ the short
F-SozU-14, as we anticipate that a reduction of items
will contribute to patients’ compliance in answering
the whole questionnaire pack, and reduce potential
burden arising from high time exposure.
Self-efficacy
Patients’ self-efficacy will be measured with the German
version of the Self-Efficacy for Managing Chronic Disease
6-Item Scale (SES6G). This assessment tool has provided
high internal consistency and good convergent construct
validity [46]. Patients will be asked on 10-point Likert
scales to indicate how confident they perceive themselves
in handling their chronic illness.
Patient competence
The concept of patient competence will be measured
with the FEPK 2–57, which is a 57-item questionnaire
involving five problem-focused and three emotion-
focused subscales [34]. Patients will be asked on 5-point
Likert scales how they perceive their competencies in
coping with their disease with regard to employing self-
managing strategies and communication with others.
The questionnaire has provided satisfactory reliability;
while external validity still needs to be evaluated and a
short version composed.Spiritual wellbeing
Cancer patients’ quality of life [47] and CAM use [48]
are associated with their spiritual well-being, which we
will measure with the ‘Spiritual and Religious Attitudes
in Dealing with Illness’ (SpREUK) instrument [49,50].
On 5-point Likert scales, participants are asked the ex-
tent to which they experienced aspects of search, faith,
and reflection in the past week; thereby assessing how
their confrontation with an existential illness resulted in
their essential need to find meaningful answers and prac-
tices. We will employ the short form SpREUK-15 , which
has provided high internal consistency and is considered to
be suited for oncology populations [51].
Patient satisfaction
For evaluating patients’ perceptions on the quality of
medical and nursing care, we will employ the EORTC-
QLQ-PATSAT32. This questionnaire has been validated
in a cross-cultural context and provides excellent values
for reliability and convergent validity [52].
Quality of life (patients’ significant other)
The WHOQOL-BREF is a validated assessment tool
for measuring generic quality of life in individuals
[53]. We will employ this internationally widely
employed tool to assess if patients’ HRQoL correlates
with the QoL of their significant others (SOs). In
addition, patients’ SOs will be asked to answer the
German version of the Caregiver Quality of Life Index-
Cancer (CQOLC), an instrument measuring specific
and more accurate areas of the quality of life of signifi-
cant others of patients with cancer [54]. The German
translation is accessible in the Patient-Reported Outcome
and Quality of Life Instruments Database (PROQOLID),
but the psychometric properties of this version have
not yet been reported [55].
Accompanying research on economic data
Kligler and colleagues have shown that an integrative
medicine approach including holistic nursing and a heal-
ing environment in an inpatient oncology setting can
decrease anxiety, fatigue, and the use of medications
resulting in substantial cost savings in the care of oncol-
ogy patients [56]. Such evidence provides the rationale
for including health economic analyses into our study
plan. Secondary health economy-related endpoints will
include the following:
1. the cost of study treatments in intervention and
control groups,
2. the total cost of health care utilization and
productivity losses in intervention and control
groups during follow-up,
3. the cost-effectiveness of trial intervention,
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intervention and control groups during follow-up,
and
5. the cost per QALY in intervention and control
groups.
The health economy analyses include the following
steps:
1. the assessment of the cost of the trial related
intervention in the experimental groups and costs in
the control groups,
2. the collection of health service utilization data in the
control and intervention groups during the follow-up,
3. the assessment of longitudinal HRQoL data for
transformation into preference measures and
calculation of QALYs lost or gained during the
follow-up, in order to calculate costs per QALY of
interventions and controls, and
4. the calculation of the incremental cost-effectiveness
ratio (ICER), cost-effectiveness acceptability curves
(CEAC) and willingness-to-pay levels.
For collecting data on health services utilization dur-
ing the follow-up, a scale [57] applied in international
research will be adapted to the specific conditions of the
German health care system and applied in the study
sample (Mannheimer Module RV). To calculate QALYs,
preferences generated from the EORCT-QLQ-C30 data
will be used for patients [58], and WHOQOL-BREF data
for patients’ SOs [53,59].
Side-effects of chemotherapy
Adverse events of the conventional cancer treatment will
be documented according to the international standard of
the National Cancer Institute (NCI) Common Termin-
ology Criteria for Adverse Events [60].
Sample size and power considerations
Sample size was calculated for the global quality of life
(Items 29 and 30 of EORTC-QLQ-C30) and was based on
a two-group comparison using Student’s t-test because no
reliable estimate of the correlation between repeated mea-
sures was available. Following the recommendation by
Cocks et al. [36], a difference of 10 points between the
randomized groups was considered clinically important
(that is, ‘smallest medium difference’). This difference cor-
responds to a standardized effect of d = 0.4 according to
Cohen. To detect d = 0.4 with a power of 1 - β = 80%
using a two-sample t-test at a two-sided significance
level α = 5%, a total of 200 patients in the randomized
arms (100 per arm) will be required. The sample size
calculation was performed using nQuery Advisor V7.0.
We expect the power of the main statistical analysis tobe higher than 80% because repeated measurements
will be taken into account and the analysis will be add-
itionally adjusted for relevant covariates such as
HRQoL at baseline.
We assume that 40% of the patients have no or no
strong preference and thus will be randomized. About
60% of the patients are assumed to have a strong prefer-
ence for the CAM intervention. Therefore, we need to
include 200 patients in the randomized arms (100 per
arm) and we expect to include about 300 patients in the
observational arms. Assuming up to 15% of patients may
not have primary outcome data available, the sample size
was adjusted to a total of 236 patients in the randomized
arms (118 per arm) and about 354 patients in the obser-
vational arms.
Data analysis
According to Schmoor et al. [61], the first analysis step of
PRPP trials is the classical analysis of the randomized
patients. These are the basic results of the trial and these
results have internal validity. The primary objective of the
present study is to determine the effectiveness of a com-
plex nursing care intervention on CAM in women with
breast and gynecologic cancer undergoing chemotherapy,
and to show that the complex intervention results in
higher HRQoL, compared to usual nursing care alone.
The primary endpoint is the global HRQoL subscale of
the EORTC QLQ-C30 questionnaire and is assumed to
follow an approximate normal distribution [35].
A linear mixed model will be used to compare
HRQoL under chemotherapy between the two random-
ized groups from treatment start to long-term follow-up
(T1 to T4). This model takes into account the hierarchical
structure of the data with repeated measurements nested
in patients (that is, patients will be included as random ef-
fects in the intercept). Fixed effects will include treatment
(usual nursing care versus complex nursing care interven-
tion on CAM), the time of measurement (T1 to T4), the
interaction of treatment and time, as well as the HRQoL
baseline scores at T1, and the stratification variables stage
of cancer (non-metastatic versus metastatic) and study
centre (university hospital versus community hospital).
Because the measurements are not equidistant in time, an
unstructured covariance matrix will be estimated. For the
main effect of treatment, the null hypothesis of no differ-
ence in group averages will be tested at the two-sided sig-
nificance level of α = 0.05. Differences between short-term
and long-term effects will be assessed by the interaction of
treatment and time. The primary analysis will be per-
formed for all randomized patients according to the
intention-to-treat principle. As sensitivity analysis, the
analysis will be repeated in the per protocol set, excluding
patients with major protocol violations. Because longitu-
dinal mixed models make use of the missing at random
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missing data in the primary analysis. However, sensitiv-
ity analyses will be conducted to assess the impact of
missing data (for example, omitted measurements at
some time point) by various approaches, including for
example the ICA-r method (imputation according to
reasons for missingness [62]), the last observation
carried forward, and multiple imputation. Model fit
will be assessed by visual inspection of residual plots.
Descriptive analyses of secondary endpoints will be
performed. All estimates will be presented with 95%
confidence intervals. External validity will be assessed
by comparing the randomized with the non-
randomized patients. The comparison of the observa-
tional group will thereby facilitate the applicability of
the results. The central part of the second analysis step
is, thus, to assess whether treatment effects observed in
the randomized patients are comparable with those ob-
served in the two observational arms. If there are meas-
urable differences between these two groups with
regard to prognostic factors, the effect of these differ-
ences will be examined using propensity score methods.
Propensity scores will be determined that reflect the
patients’ preferences.Quality assurance
The study is planned in accordance with the German
data protection law and ICH/GCP guidelines. External
monitoring and consultations with an advisory board
will ensure patient safety and highest possible data
quality. Monitoring visits will be conducted on a regu-
lar basis by independent qualified study nurses of the
Department of General Practice and Health Services
Research, University Hospital Heidelberg. This moni-
toring will include pre-study-visits and monitoring
visits using standard operating procedures with moni-
toring of complete eCRFs of at least 10% of the patients
included and of core and safety data of the remaining
patients. Furthermore, study nurses will check the
provision of the interventions in both study sites on a
random basis.
All instruments will be piloted to assure readability
and limit missing item response. Survey instruments will
be provided by the coordinating centre (Department of
General Practice and Health Services Research) to
minimize printing error or layout variation. The coord-
inating centre will be responsible for scanning of all
questionnaires from both study sites, for query manage-
ment and data consistency check. This study is sup-
ported by an external advisory board including experts/
representatives of CAM, clinical pharmacology, oncol-
ogy, study methodology, nursing science, statistical
science and the patient perspective.Discussion
The CONGO study is the first prospective partially ran-
domized patient preference trial investigating the impact
of a nurse-led intervention involving both clinic and
home-based CAM use in breast and gynecologic cancer
patients undergoing chemotherapy in two outpatient can-
cer services. The findings from this study will add to the
growing body of evidence of the effectiveness of CAM in-
terventions for individuals with cancer, by testing several
aspects relevant for the implementation of patient-
centered models of integrative healthcare: (1) patients will
receive cancer care including CAMs and individual coun-
seling on CAM by oncology nurses; (2) patients’ prefer-
ence to receive the CAM intervention will be considered;
(3) patients’ empowerment resources will be activated in
the initial and following individualized counseling inter-
views, by receiving standardized CAM instructions and an
additional information booklet including evidence-based
CAM for home use; (4) The effect of the intervention will
be measured on HRQoL and a range of other physical and
psychosocial symptoms; (5) Sustainability and long-term
effects of this intervention will be assessed by follow-up;
(6) A thorough process evaluation will provide explanation
on succeeding or impedimental factors impacting con-
comitantly on the process of the intervention.
The majority of breast and gynecologic cancer patients
receive adjuvant or neoadjuvant chemotherapy, which may
help to cure their cancer, or prolong life, but also affects
their HRQoL due to treatment side-effects or psychosocial
concerns [63]. Research consistently demonstrates that
cancer patients have a high interest in complementing their
conventional cancer treatment by using CAMs [3,5], and
some integrative cancer centers have incorporated patients’
preference in providing counseling and methods reflecting
a holistic treatment approach [18]. There is, however, a
lack of research investigating the effects of such inte-
grated services on a range of patient-centered outcomes
in cancer patients treated with chemotherapy [64]. Pre-
vious randomized trials mostly investigated the efficacy
of one CAM therapy on primary and secondary out-
comes [65-68]. Likewise, other effectiveness studies,
including nonpharmacologic interventions focused on
investigating cognitive or educational programs, how-
ever, excluded CAM therapies [69,70] not knowing if
patients applied CAM nevertheless. The current study
aims to address this aspect by supplying patients in the
control group with a patient diary to collect data
related to physical and psychological symptoms as well
as other supportive therapies patients may apply. While
many intervention studies with cancer patients aimed
to target cancer-related fatigue (CRF) [71-73], the
CONGO study is designed to investigate if cancer pa-
tients’ and their significant others’ quality of life will be
affected by the complex CAM nursing intervention.
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study will consider several elements when analyzing par-
ticipants’ HRQoL. The intervention targets common
symptoms of patients undergoing chemotherapy. To
address these symptoms, a range of CAM interventions
will be administered to the patient in the outpatient
centre at each cycle of chemotherapy. Some of these
CAM interventions are already part of the clinics’
nursing standards [20]; however, they have not yet been
standardized and evaluated. In the current study, the
patients will also receive counseling on how to apply
some of these CAM interventions at home between cy-
cles. Plus, patients will receive an evidence-based infor-
mation booklet on different CAM interventions as well
as contact sources on other external CAM providers in
case they prefer to pursue the wide CAM spectrum
further on. As a chemotherapy regimen lasts very long
(for example, 24 weeks) the patient will visit the out-
patient clinic every 3 to 4 weeks that is, 6 to 8 times. It
is likely that the patient builds a relationship with the
assigned CAM nurse caring for her, which might also
add to improvements in HRQoL. In the randomized
group, we can account for potential confounders, and
analyze the primary and secondary outcomes, but we
cannot explain which single element of the interact-
ing intervention agents has the highest impact on
changes in HRQoL.
The shift from inpatient to outpatient cancer treat-
ment has increased awareness of patients’ self-care
strategies and also of their significant others (SOs) in-
cluding family members and close friends [74,75].
Cancer has become a family disease affecting not only
the individual with the cancer diagnosis, but also in-
volving their SOs who often are experiencing high
levels of distress [76] while accompanying and support-
ing their loved one going through the treatment stages
and adjusting to a new life situation [77]. A strength of
the current study is the consideration of patients’ SO,
whose QoL will be assessed T1, T3, and T4; and who
will be interviewed during the process evaluation to
gain a better understanding about their perceptions on
the cancer patient’s experiences with the complex nurs-
ing care intervention on CAM. The interventions have
been primarily composed for the patient receiving chemo-
therapy, and therefore exclude couple-based methods;
however, some of these home-based interventions can be
administered by the SOs (for example, preparing the tea,
conducting the massage). Thus, the current study will pro-
vide further information in highlighting if the shared
CAM use contributes to bonding and improvements of
QoL in cancer patients’ SOs [74,75].
A further strength of the CONGO study is the inter-
professional aspect, which takes into account the collab-
oration between health professionals in the design of thestudy as well as in the composition of the complex
nurse-led intervention. To our knowledge, this is one of
the first nurse-led CAM intervention studies in
Germany that can assess nurses’ relevant contribution in
promoting HRQoL during cancer therapy.
Another unique aspect of the CONGO study is pa-
tients’ choice of the study arm. Due to high interest and
prevalence of CAM in cancer populations, we expect
that 60% of participants will decide for the intervention
and will therefore be allocated into the observational
study arm. This study arm will be analyzed descriptively
and will be used to assess the external validity of the
study results. However, it will be a challenge to recruit
enough participants for the randomized arm.
The logistic implementation of the CONGO study
presents challenges in recruiting the two centers and
the healthcare staff involved. Several meetings, involv-
ing mutual exchange visits of the involved nursing staff
have taken place to facilitate the planning and coordin-
ation of the procedure of the study, and to find solu-
tions for recruiting enough patients for the randomized
arm. During these pre-study meetings, how the study
participants can be recruited without any interruptions
for the outpatient clinic routine has been elaborated, as
well as how to care for and treat the study participants
of the different study arms - with and without receiving
the intervention. The organization of the study requires
a flexible schedule of the CAM-trained nurses, as they
have to inform the patients about the study, collect
their informed consent, conduct the initial counseling
and follow-up interviews, as well as conduct the inter-
vention while the patient receives chemotherapy. In
addition, it will be expected that the CAM-trained
nurse cares about the data collection and documents
the implementation of the intervention in an electronic
case report file (eCRF).
In summary, the CONGO study has been designed to
evaluate the effectiveness of an intervention involving
CAM therapies and counseling on CAM as comple-
menting the supportive care of breast and gynecologic
cancer patients undergoing chemotherapy. It is hypothe-
sized that this intervention increases HRQoL and
clustered symptoms over the chemotherapy regimen and
follow-up in this outpatient population, and that this is
highly relevant to know in the context of promoting and
advancing integrative cancer care/clinics.
Trial status
The trial has received funding in December 2013 and
ethical clearance in Mai 2014. At the time of submission
of this protocol, the intervention has been standardized
and nursing staff has been trained. Recruitment began
in July 2014. We anticipate that all data will be col-
lected by May 2016.
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